JP2009528345A5 - - Google Patents

Download PDF

Info

Publication number
JP2009528345A5
JP2009528345A5 JP2008557240A JP2008557240A JP2009528345A5 JP 2009528345 A5 JP2009528345 A5 JP 2009528345A5 JP 2008557240 A JP2008557240 A JP 2008557240A JP 2008557240 A JP2008557240 A JP 2008557240A JP 2009528345 A5 JP2009528345 A5 JP 2009528345A5
Authority
JP
Japan
Prior art keywords
gene
arylaliphatic
pharmaceutical composition
aliphatic
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008557240A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009528345A (ja
JP5468782B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SG2006/000350 external-priority patent/WO2007100304A1/en
Publication of JP2009528345A publication Critical patent/JP2009528345A/ja
Publication of JP2009528345A5 publication Critical patent/JP2009528345A5/ja
Application granted granted Critical
Publication of JP5468782B2 publication Critical patent/JP5468782B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008557240A 2006-03-02 2006-11-15 癌治療と幹細胞調節のための方法 Expired - Fee Related JP5468782B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77853206P 2006-03-02 2006-03-02
US60/778,532 2006-03-02
PCT/SG2006/000350 WO2007100304A1 (en) 2006-03-02 2006-11-15 Methods for cancer therapy and stem cell modulation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013015684A Division JP2013121974A (ja) 2006-03-02 2013-01-30 癌治療と幹細胞調節のための方法
JP2013213366A Division JP5902138B2 (ja) 2006-03-02 2013-10-11 癌治療と幹細胞調節のための方法

Publications (3)

Publication Number Publication Date
JP2009528345A JP2009528345A (ja) 2009-08-06
JP2009528345A5 true JP2009528345A5 (https=) 2010-01-07
JP5468782B2 JP5468782B2 (ja) 2014-04-09

Family

ID=38459334

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008557240A Expired - Fee Related JP5468782B2 (ja) 2006-03-02 2006-11-15 癌治療と幹細胞調節のための方法
JP2013015684A Pending JP2013121974A (ja) 2006-03-02 2013-01-30 癌治療と幹細胞調節のための方法
JP2013213366A Expired - Fee Related JP5902138B2 (ja) 2006-03-02 2013-10-11 癌治療と幹細胞調節のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2013015684A Pending JP2013121974A (ja) 2006-03-02 2013-01-30 癌治療と幹細胞調節のための方法
JP2013213366A Expired - Fee Related JP5902138B2 (ja) 2006-03-02 2013-10-11 癌治療と幹細胞調節のための方法

Country Status (7)

Country Link
US (2) US8058258B2 (https=)
EP (2) EP1993553B1 (https=)
JP (3) JP5468782B2 (https=)
AU (1) AU2006339445A1 (https=)
SG (1) SG170041A1 (https=)
TW (1) TW200812590A (https=)
WO (1) WO2007100304A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909630A (zh) * 2007-11-02 2010-12-08 新加坡科技研究局 预防和治疗肿瘤的方法和化合物
EP2334179A4 (en) * 2008-09-08 2012-09-26 Merck Sharp & Dohme AHCY-HYDROLASE INHIBITOR FOR THE TREATMENT OF HYPERHOMOCYSTEINEMIA
EP2331543A4 (en) * 2008-09-26 2013-06-19 Agency Science Tech & Res 3-deazaneplanocin DERIVATIVES
US8895526B2 (en) * 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
EP2646455A4 (en) * 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012075381A1 (en) 2010-12-03 2012-06-07 Epizyme, Inc. Substituted purine and 7 - deazapurine compounds as modulators of epigenetic enzymes
WO2012159085A2 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
WO2013036846A2 (en) * 2011-09-09 2013-03-14 Koronis Pharmaceuticals, Incorporated N4 derivatives of deoxycytidine prodrugs
CA2887461A1 (en) * 2012-07-09 2014-01-16 Metheor Therapeutics Corporation Oligonucleotide inhibitors of dna methyltransferases and their use in treating diseases
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
US9597348B2 (en) 2012-09-06 2017-03-21 Epizyme, Inc. Method of treating leukemia
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
US20160010059A1 (en) * 2013-03-06 2016-01-14 The Regents Of The University Of California EXPANSION OF HEMATOPOIETIC PROGENITOR CELLS BY HISTONE METHYLTRANSFERASE G9a INHIBITION
JP2016517426A (ja) 2013-03-15 2016-06-16 エピザイム，インコーポレイティド 置換プリン化合物の合成方法
WO2016022563A1 (en) 2014-08-04 2016-02-11 Auburn University Enantiomers of the 1',6'-isomer of neplanocin a
WO2016149299A1 (en) * 2015-03-16 2016-09-22 Epinova Therapeutics Corp. Therapeutic compounds that suppress protein arginine methyltransferase activity for reducing tumor cell proliferation
WO2020055663A1 (en) * 2018-09-11 2020-03-19 The Texas A&M University System L-oligonucleotide inhibitors of polycomb repressive complex 2 (prc2)
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
WO2023249714A1 (en) * 2022-06-24 2023-12-28 Memorial Sloan-Kettering Cancer Center Therapeutic compositions and methods for activating double stranded rna response in cancer patients via dnmt1 targeted therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510260A (en) 1893-12-05 Electric-arc-lighting system
US4968690A (en) 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
WO1999048527A1 (en) 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
EP1536688B1 (en) 2002-09-13 2011-12-28 The Board Of Trustees Of The Leland Stanford Junior University Mammalian megakaryocyte progenitor cell
WO2004046312A2 (en) 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
US20050245559A1 (en) 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
US20050266093A1 (en) 2004-04-27 2005-12-01 Mohapatra Shyam S Nanogene therapy for cell proliferation disorders
MX2007000770A (es) 2004-07-20 2007-03-26 Schering Corp Induccion de apoptosis en celulas tumorales que expresan el receptor tipo toll.

Similar Documents

Publication Publication Date Title
JP2009528345A5 (https=)
Fathallah et al. Induction of fetal hemoglobin in the treatment of sickle cell disease
AU2003219803B8 (en) Method of treating TRX mediated diseases
Miranda et al. Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery
JP2009539862A5 (https=)
US20170027971A1 (en) Use of hdac and/or dnmt inhibitors for treatment of ischemic injury
JP2016510999A5 (https=)
JP2009545310A5 (https=)
CN110917362A (zh) 核酸输送的区室化方法及其组合物和应用
WO2011113013A2 (en) Methods and compositions for treating viral or virally-induced conditions
MY160652A (en) Pharmaceutical composition for oral administration
JP2016517888A5 (https=)
JP2017535521A5 (https=)
EP2012801A2 (en) Gemcitabine combination therapy
JP2014532722A5 (https=)
JP2014505107A5 (https=)
JP2012107063A5 (https=)
Fang Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers
JP2012512157A5 (https=)
Hanikoglu et al. Natural product inhibitors of histone deacetylases as new anticancer agents
WO2012063005A3 (fr) Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation
CN102441167B (zh) 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
ES2964286T3 (es) Método de tratamiento de la Esteatohepatitis no alcohólica avanzada
CA2798420A1 (en) Combination of an nsaid and an amino acid
JP6100510B2 (ja) 抗感冒剤